GBT [NASD]
Global Blood Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.00 Insider Own1.90% Shs Outstand65.59M Perf Week0.66%
Market Cap4.51B Forward P/E- EPS next Y-2.85 Insider Trans-0.25% Shs Float61.77M Perf Month86.27%
Income-322.50M PEG- EPS next Q-1.11 Inst Own- Short Float15.16% Perf Quarter161.57%
Sales234.90M P/S19.20 EPS this Y-19.30% Inst Trans3.98% Short Ratio3.54 Perf Half Y117.66%
Book/sh1.80 P/B37.24 EPS next Y39.10% ROA-39.20% Target Price66.63 Perf Year142.02%
Cash/sh7.69 P/C8.72 EPS next 5Y37.00% ROE-170.40% 52W Range21.65 - 73.02 Perf YTD129.04%
Dividend- P/FCF- EPS past 5Y-14.20% ROI-37.10% 52W High-8.19% Beta0.90
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin98.10% 52W Low209.65% ATR3.00
Employees457 Current Ratio6.90 Sales Q/Q50.40% Oper. Margin- RSI (14)90.19 Volatility0.51% 6.34%
OptionableYes Debt/Eq4.91 EPS Q/Q-12.60% Profit Margin- Rel Volume2.02 Prev Close66.75
ShortableYes LT Debt/Eq4.91 EarningsAug 08 AMC Payout- Avg Volume2.64M Price67.04
Recom1.90 SMA2051.62% SMA5090.45% SMA200111.25% Volume5,347,002 Change0.43%
Aug-08-22Upgrade Canaccord Genuity Hold → Buy $40 → $72
Aug-08-22Downgrade William Blair Outperform → Mkt Perform
Mar-28-22Resumed Wedbush Outperform $138 → $71
Dec-07-21Upgrade William Blair Mkt Perform → Outperform
Oct-07-21Initiated Jefferies Buy $68
Aug-04-21Upgrade Truist Hold → Buy $50
Jun-28-21Downgrade JP Morgan Overweight → Neutral $70 → $36
Apr-14-21Initiated SVB Leerink Outperform $54
Mar-12-21Initiated Wolfe Research Outperform $67
Feb-25-21Downgrade William Blair Outperform → Mkt Perform
Jan-20-21Downgrade Piper Sandler Overweight → Neutral $75 → $50
Dec-15-20Resumed H.C. Wainwright Buy $75
Dec-03-20Initiated RBC Capital Mkts Outperform $75
Nov-06-20Downgrade Raymond James Outperform → Mkt Perform
Oct-06-20Initiated Evercore ISI Outperform $102
Aug-25-20Initiated Raymond James Outperform $115
Jul-20-20Initiated ROTH Capital Buy $129
Jul-13-20Initiated BofA Securities Buy $92
Jul-01-20Upgrade Goldman Neutral → Buy $91 → $103
Apr-28-20Initiated Stifel Buy $112
Aug-12-22 09:50AM  
Aug-09-22 04:46PM  
03:59PM  
11:02AM  
Aug-08-22 04:07PM  
02:51PM  
12:58PM  
12:07PM  
11:48AM  
11:09AM  
10:05AM  
08:07AM  
07:22AM  
06:57AM  
06:52AM  
06:48AM  
06:48AM  
06:45AM  
06:37AM  
Aug-05-22 05:22PM  
04:49PM  
04:11PM  
01:35PM  
01:09PM  
12:20PM  
12:08PM  
11:58AM  
11:44AM  
07:53AM  
Aug-04-22 04:05PM  
02:42PM  
10:44AM  
09:07AM  
Aug-03-22 04:05PM  
Jul-31-22 09:35AM  
Jul-29-22 08:00AM  
Jul-27-22 10:01AM  
Jul-26-22 10:01AM  
03:01AM  
Jul-14-22 08:00AM  
Jul-13-22 08:00AM  
Jul-07-22 04:05PM  
Jul-05-22 03:55PM  
Jun-30-22 11:47AM  
Jun-29-22 03:27PM  
08:00AM  
Jun-16-22 08:00AM  
Jun-13-22 08:00AM  
Jun-10-22 04:06PM  
03:00AM  
Jun-09-22 09:58AM  
Jun-08-22 11:30AM  
Jun-07-22 11:23AM  
Jun-06-22 10:00AM  
08:00AM  
Jun-03-22 11:32AM  
Jun-02-22 04:05PM  
Jun-01-22 04:05PM  
May-26-22 11:18AM  
May-12-22 10:00AM  
May-11-22 10:24AM  
May-05-22 06:40PM  
04:05PM  
04:05PM  
10:22AM  
May-04-22 11:30PM  
05:25PM  
04:05PM  
Apr-28-22 08:20AM  
Apr-27-22 03:03PM  
08:00AM  
Apr-11-22 02:35PM  
Apr-08-22 11:22AM  
Apr-07-22 04:05PM  
Apr-06-22 02:30AM  
Apr-03-22 09:10PM  
Mar-29-22 03:17PM  
12:06PM  
Mar-25-22 11:30AM  
Mar-24-22 04:05PM  
Mar-23-22 12:45PM  
Mar-10-22 04:05PM  
Mar-03-22 08:00AM  
Mar-01-22 11:00AM  
Feb-28-22 08:00AM  
Feb-24-22 11:14AM  
Feb-23-22 05:25PM  
04:05PM  
Feb-22-22 12:01PM  
Feb-16-22 04:05PM  
09:41AM  
06:00AM  
Feb-08-22 06:46AM  
Feb-03-22 08:00AM  
Jan-27-22 03:00AM  
Jan-10-22 08:00AM  
Jan-07-22 04:49PM  
Jan-06-22 08:00AM  
Jan-04-22 08:00AM  
Dec-23-21 05:52PM  
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Svoronos DawnDirectorJun 21Sale27.241,90851,9835,376Jun 22 06:00 PM
Pizzo Philip A.DirectorJun 21Sale27.251,26034,3379,112Jun 22 06:00 PM
Morrison Scott WDirectorSep 09Sale30.214,800145,0033,037Sep 10 08:00 PM